Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
This study is to evaluate available local data in Iraq patients with moderate-to-severe
 plaque psoriasis on Enbrel treatment with regards to efficacy, treatment for PsO who have
 difficult to treat sites at presentation.
Inclusion Criteria:

 -  Moderate-to-severe plaque psoriasis patients whom have been receiving etanercept for
 at least 1 year duration.

 -  Have difficult to treat sites at presentation.

 -  Age ≥18 years.

 -  No history of using other biological treatments, other than etanercept for the
 treatment of moderate-to-severe PsO.

 Exclusion Criteria:

 -  Etanercept use for treatment of moderate-to-severe PsO less than 1 year duration.

 -  Previous use of another biological treatment for treatment of moderate-to-severe PsO.